Economics, externalities and rare disease
Special combined efforts addressing rare diseases should apply economic principles and methods to maximize returns to research and investment. Four opportunities exist: (1) exploiting treatment spillovers; (2) encouraging institutional networking and knowledge-sharing; (3) recognizing shared molecul...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | Rare |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S295000872400019X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850113876385857536 |
|---|---|
| author | Carlisle Ford Runge James Campbell Carlisle P. Runge Reena V. Kartha |
| author_facet | Carlisle Ford Runge James Campbell Carlisle P. Runge Reena V. Kartha |
| author_sort | Carlisle Ford Runge |
| collection | DOAJ |
| description | Special combined efforts addressing rare diseases should apply economic principles and methods to maximize returns to research and investment. Four opportunities exist: (1) exploiting treatment spillovers; (2) encouraging institutional networking and knowledge-sharing; (3) recognizing shared molecular and genetic etiologies; (4) organizing resulting clusters and baskets for scaling trials, research, diagnosis and treatment. |
| format | Article |
| id | doaj-art-a390b86b96844f728b9acde21497902e |
| institution | OA Journals |
| issn | 2950-0087 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Rare |
| spelling | doaj-art-a390b86b96844f728b9acde21497902e2025-08-20T02:37:02ZengElsevierRare2950-00872024-01-01210003610.1016/j.rare.2024.100036Economics, externalities and rare diseaseCarlisle Ford Runge0James Campbell1Carlisle P. Runge2Reena V. Kartha3Department of Applied Economics and Law, University of Minnesota, Twin Cities, USA; Corresponding author.School of Public Health, University of Minnesota, Twin Cities, USABinera, Inc. consulting for Biomedical Advanced Research and Development Authority (BARDA), U. S. Department of Health and Human Services, Washington DC, USACollege of Pharmacy, Center for Orphan Drug Research. Department of Experimental and Clinical Pharmacology, University of Minnesota, Twin Cities, USASpecial combined efforts addressing rare diseases should apply economic principles and methods to maximize returns to research and investment. Four opportunities exist: (1) exploiting treatment spillovers; (2) encouraging institutional networking and knowledge-sharing; (3) recognizing shared molecular and genetic etiologies; (4) organizing resulting clusters and baskets for scaling trials, research, diagnosis and treatment.http://www.sciencedirect.com/science/article/pii/S295000872400019XSpilloversAffinity clustersBasket trialsInvestment, orphan drugs |
| spellingShingle | Carlisle Ford Runge James Campbell Carlisle P. Runge Reena V. Kartha Economics, externalities and rare disease Rare Spillovers Affinity clusters Basket trials Investment, orphan drugs |
| title | Economics, externalities and rare disease |
| title_full | Economics, externalities and rare disease |
| title_fullStr | Economics, externalities and rare disease |
| title_full_unstemmed | Economics, externalities and rare disease |
| title_short | Economics, externalities and rare disease |
| title_sort | economics externalities and rare disease |
| topic | Spillovers Affinity clusters Basket trials Investment, orphan drugs |
| url | http://www.sciencedirect.com/science/article/pii/S295000872400019X |
| work_keys_str_mv | AT carlislefordrunge economicsexternalitiesandraredisease AT jamescampbell economicsexternalitiesandraredisease AT carlisleprunge economicsexternalitiesandraredisease AT reenavkartha economicsexternalitiesandraredisease |